Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Methylation patterns in serum DNA for early identification of disseminated breast cancer

M. Widschwendter, I. Evans, A. Jones, S. Ghazali, D. Reisel, A. Ryan, A. Gentry-Maharaj, M. Zikan, D. Cibula, J. Eichner, M. Alunni-Fabbroni, J. Koch, WJ. Janni, T. Paprotka, T. Wittenberger, U. Menon, B. Wahl, B. Rack, H. Lempiäinen,

. 2017 ; 9 (1) : 115. [pub] 20171222

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001024

BACKGROUND: Monitoring treatment and early detection of fatal breast cancer (BC) remains a major unmet need. Aberrant circulating DNA methylation (DNAme) patterns are likely to provide a highly specific cancer signal. We hypothesized that cell-free DNAme markers could indicate disseminated breast cancer, even in the presence of substantial quantities of background DNA. METHODS: We used reduced representation bisulfite sequencing (RRBS) of 31 tissues and established serum assays based on ultra-high coverage bisulfite sequencing in two independent prospective serum sets (n = 110). The clinical use of one specific region, EFC#93, was validated in 419 patients (in both pre- and post-adjuvant chemotherapy samples) from SUCCESS (Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial) and 925 women (pre-diagnosis) from the UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening) population cohort, with overall survival and occurrence of incident breast cancer (which will or will not lead to death), respectively, as primary endpoints. RESULTS: A total of 18 BC specific DNAme patterns were discovered in tissue, of which the top six were further tested in serum. The best candidate, EFC#93, was validated for clinical use. EFC#93 was an independent poor prognostic marker in pre-chemotherapy samples (hazard ratio [HR] for death = 7.689) and superior to circulating tumor cells (CTCs) (HR for death = 5.681). More than 70% of patients with both CTCs and EFC#93 serum DNAme positivity in their pre-chemotherapy samples relapsed within five years. EFC#93-positive disseminated disease in post-chemotherapy samples seems to respond to anti-hormonal treatment. The presence of EFC#93 serum DNAme identified 42.9% and 25% of women who were diagnosed with a fatal BC within 3-6 and 6-12 months of sample donation, respectively, with a specificity of 88%. The sensitivity with respect to detecting fatal BC was ~ 4-fold higher compared to non-fatal BC. CONCLUSIONS: Detection of EFC#93 serum DNAme patterns offers a new tool for early diagnosis and management of disseminated breast cancers. Clinical trials are required to assess whether EFC#93-positive women in the absence of radiological detectable breast cancers will benefit from anti-hormonal treatment before the breast lesions become clinically apparent.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001024
003      
CZ-PrNML
005      
20190118124125.0
007      
ta
008      
190107s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13073-017-0499-9 $2 doi
035    __
$a (PubMed)29268762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Widschwendter, Martin $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, UK. M.Widschwendter@ucl.ac.uk.
245    10
$a Methylation patterns in serum DNA for early identification of disseminated breast cancer / $c M. Widschwendter, I. Evans, A. Jones, S. Ghazali, D. Reisel, A. Ryan, A. Gentry-Maharaj, M. Zikan, D. Cibula, J. Eichner, M. Alunni-Fabbroni, J. Koch, WJ. Janni, T. Paprotka, T. Wittenberger, U. Menon, B. Wahl, B. Rack, H. Lempiäinen,
520    9_
$a BACKGROUND: Monitoring treatment and early detection of fatal breast cancer (BC) remains a major unmet need. Aberrant circulating DNA methylation (DNAme) patterns are likely to provide a highly specific cancer signal. We hypothesized that cell-free DNAme markers could indicate disseminated breast cancer, even in the presence of substantial quantities of background DNA. METHODS: We used reduced representation bisulfite sequencing (RRBS) of 31 tissues and established serum assays based on ultra-high coverage bisulfite sequencing in two independent prospective serum sets (n = 110). The clinical use of one specific region, EFC#93, was validated in 419 patients (in both pre- and post-adjuvant chemotherapy samples) from SUCCESS (Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial) and 925 women (pre-diagnosis) from the UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening) population cohort, with overall survival and occurrence of incident breast cancer (which will or will not lead to death), respectively, as primary endpoints. RESULTS: A total of 18 BC specific DNAme patterns were discovered in tissue, of which the top six were further tested in serum. The best candidate, EFC#93, was validated for clinical use. EFC#93 was an independent poor prognostic marker in pre-chemotherapy samples (hazard ratio [HR] for death = 7.689) and superior to circulating tumor cells (CTCs) (HR for death = 5.681). More than 70% of patients with both CTCs and EFC#93 serum DNAme positivity in their pre-chemotherapy samples relapsed within five years. EFC#93-positive disseminated disease in post-chemotherapy samples seems to respond to anti-hormonal treatment. The presence of EFC#93 serum DNAme identified 42.9% and 25% of women who were diagnosed with a fatal BC within 3-6 and 6-12 months of sample donation, respectively, with a specificity of 88%. The sensitivity with respect to detecting fatal BC was ~ 4-fold higher compared to non-fatal BC. CONCLUSIONS: Detection of EFC#93 serum DNAme patterns offers a new tool for early diagnosis and management of disseminated breast cancers. Clinical trials are required to assess whether EFC#93-positive women in the absence of radiological detectable breast cancers will benefit from anti-hormonal treatment before the breast lesions become clinically apparent.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x krev $x genetika $7 D014408
650    _2
$a nádory prsu $x krev $x genetika $x patologie $7 D001943
650    _2
$a volné cirkulující nukleové kyseliny $x genetika $7 D000073888
650    12
$a metylace DNA $7 D019175
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové cirkulující buňky $x metabolismus $x patologie $7 D009360
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Evans, Iona $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Jones, Allison $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Ghazali, Shohreh $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Reisel, Daniel $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Ryan, Andy $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Gentry-Maharaj, Aleksandra $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Zikan, Michal $u Gynaecologic Oncology Center, Department of Obstetrics & Gynaecology, First Faculty of Medicine & General University Hospital, Charles University Prague, Prague, Czech Republic.
700    1_
$a Cibula, David $u Gynaecologic Oncology Center, Department of Obstetrics & Gynaecology, First Faculty of Medicine & General University Hospital, Charles University Prague, Prague, Czech Republic.
700    1_
$a Eichner, Johannes $u Genedata AG, Margarethenstrasse 38, 4053, Basel, Switzerland.
700    1_
$a Alunni-Fabbroni, Marianna $u Department of Gynaecology and Obstetrics, Klinikum Innenstadt, Ludwig-Maximilians Universitaet Muenchen, Maistrasse 11, 80337, Munich, Germany.
700    1_
$a Koch, Julian $u Department of Gynaecology and Obstetrics, Klinikum Innenstadt, Ludwig-Maximilians Universitaet Muenchen, Maistrasse 11, 80337, Munich, Germany.
700    1_
$a Janni, Wolfgang J $u Department of Gynaecology and Obstetrics, University Hospital Ulm, Prittwitzstrasse 43, 89075, Ulm, Germany.
700    1_
$a Paprotka, Tobias $u GATC Biotech AG, Jakob-Stadler-Platz 7, 78467, Konstanz, Germany.
700    1_
$a Wittenberger, Timo $u Genedata AG, Margarethenstrasse 38, 4053, Basel, Switzerland.
700    1_
$a Menon, Usha $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Wahl, Benjamin $u GATC Biotech AG, Jakob-Stadler-Platz 7, 78467, Konstanz, Germany. Boehringer Ingelheim Pharma, GmbH & Co. KG, Target Discovery Research, Biberach, Germany.
700    1_
$a Rack, Brigitte $u Department of Gynaecology and Obstetrics, Klinikum Innenstadt, Ludwig-Maximilians Universitaet Muenchen, Maistrasse 11, 80337, Munich, Germany. Department of Gynaecology and Obstetrics, University Hospital Ulm, Prittwitzstrasse 43, 89075, Ulm, Germany.
700    1_
$a Lempiäinen, Harri $u Genedata AG, Margarethenstrasse 38, 4053, Basel, Switzerland.
773    0_
$w MED00174694 $t Genome medicine $x 1756-994X $g Roč. 9, č. 1 (2017), s. 115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29268762 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190118124339 $b ABA008
999    __
$a ok $b bmc $g 1364975 $s 1039147
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 9 $c 1 $d 115 $e 20171222 $i 1756-994X $m Genome medicine $n Genome Med $x MED00174694
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace